Tanaka J, Mori A, Ohta S, Yamamoto Y, Kobayashi S, Hashino S, Kobayashi M, Asaka M, Imamura M
Haematology and Oncology; Third Department of Internal Medicine; Transfusion Medicine; Laboratory of Pathology, Cancer Institute, Hokkaido University School of Medicine, Sapporo, Japan.
Br J Haematol. 2000 Mar;108(4):778-83. doi: 10.1046/j.1365-2141.2000.01938.x.
We investigated the expression of natural killer cell receptors (NKRs) for HLA-C on peripheral blood mononuclear cells (PBMCs) in 23 allogeneic bone marrow transplantation (allo-BMT) patients to analyse the role of NKRs in alloresponse concerning graft-versus-host disease (GVHD). CD158a expression was low and there was little change in the expression after allo-BMT. Also, there was no difference in the proportion of CD158a+/CD3- after allo-BMT. In contrast, the proportion of CD158b+/CD3- cells, mainly NK cells, increased in the early stage (< 2 months) after allo-BMT and then gradually decreased (3.3 +/- 2.6% before BMT vs. 15.4 +/- 8. 6% in the early stage after BMT, 8.5 +/- 4.9% during the period 3-6 months after BMT and 7.0 +/- 3.0% > 6 months after BMT; P < 0.05). However, CD158b expression on CD3+ T cells increased 3 months after allo-BMT (1.1 +/- 1.1% before BMT vs. 5.1 +/- 7.7% during the period 3-6 months after BMT and 3.0 +/- 2.4% > 6 months after BMT, P < 0. 05). The highest percentages of CD158 expression in patients without chronic GVHD (cGVHD) and those with cGVHD were compared. The percentage of CD158b+/CD3+ cells and also that of CD158b+/CD8+ cells were significantly increased in patients with cGVHD compared with those in patients without cGVHD (2.6 +/- 2.0% vs. 8.0 +/- 11.2% and 2.3 +/- 1.5% vs. 8.3 +/- 11.7% respectively; P < 0.05). The exact clinical relevance of these CD158b-expressing cells is not clear. However, there is an interesting possibility that CD158b-expressing cells play some role in the regulation of GVHD after allo-BMT.
我们研究了23例异基因骨髓移植（allo - BMT）患者外周血单个核细胞（PBMCs）上HLA - C自然杀伤细胞受体（NKRs）的表达，以分析NKRs在与移植物抗宿主病（GVHD）相关的同种异体反应中的作用。CD158a表达较低，allo - BMT后其表达变化不大。此外，allo - BMT后CD158a + / CD3 - 的比例也没有差异。相比之下，主要为自然杀伤细胞的CD158b + / CD3 - 细胞比例在allo - BMT后的早期阶段（<2个月）增加，然后逐渐下降（BMT前为3.3±2.6%，BMT后早期为15.4±8.6%，BMT后3 - 6个月期间为8.5±4.9%，BMT后>6个月为7.0±3.0%；P < 0.05）。然而，allo - BMT后3个月，CD3 + T细胞上的CD158b表达增加（BMT前为1.1±1.1%，BMT后3 - 6个月期间为5.1±7.7%，BMT后>6个月为3.0±2.4%，P < 0.05）。比较了无慢性GVHD（cGVHD）患者和有cGVHD患者中CD158表达的最高百分比。与无cGVHD患者相比，有cGVHD患者中CD158b + / CD3 + 细胞以及CD158b + / CD8 + 细胞的百分比显著增加（分别为2.6±2.0%对8.0±11.2%和2.3±1.5%对8.3±11.7%；P < 0.05）。这些表达CD158b的细胞的确切临床相关性尚不清楚。然而，有一种有趣的可能性，即表达CD158b的细胞在allo - BMT后的GVHD调节中发挥某种作用。
